Advanced Search

Investigator Resources

Information for Research Participants
Information for Study Teams
Information for Sponsors
Institutional Review Boards
UM Policies & Procedures - HSRO/IRB
1. Preface
2. Background Topics
3. Authorities and Responsibilities
4. Conflict of Interest
5. Institutional Review Boards
6. IRB Meetings
7. General Principles for IRB Reviews
8. Definition of IRB Review Types
9. IRB Review of Initial Studies
10. IRB Review of Continuing Studies
11. Amendments
12. Closing Studies and Final Reports
13. Suspension, Termination and Administrative Closure of IRB Approved Research
14. Unanticipated Problems and Adverse Events
15. Study Violations
16. Compliance Audits
17. Data Safety Monitoring Boards
18. Ancillary Committees
19. External IRB's
20. Policies Specific to Certain Types of Research
21. Informed Consent
22. Participant Recruitment Methods, Advertising Materials and Recruitment-Relevant Payment Arrangements
23. Vulnerable Populations
24. Privacy, Security, Confidentiality and HIPAA
25. Subcontracts/Agreements for UM-Initiated Studies that Engage or Involve non-UM Institutions or Investigators
26. International Research
27. Emergency Use
28. Record Retention
Other Policies
UChart Forms & Guidance
HSRO Forms & Documents
University Fees
Ancillary Committee Information
eProst User Guide
Ethics, Federal Regulations & Guidance
Western IRB (WIRB)
About the HSRO

Basic Folder Information

27.4 Emergency Use and Informed Consent

approval date

Review Responsibility:

IRB Policy and Procedure Committee

Current Approval Date:

August 24, 2008


Even for an emergency use, the investigator is required to obtain informed consent of the subject or the subject’s legally authorized representative, unless both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing all of the following [21 CFR 50.23(a)]:

  1. The subject is confronted by a life-threatening situation necessitating the use of the test article.
  2. Informed consent cannot be obtained because of an inability to communicate with or to obtain legally effective consent from the subject.
  3. Time is not sufficient to obtain consent from the subject’s legal representative.
  4. No alternative method of approved or generally recognized therapy is available that provides an equal or greater likelihood of saving the subject’s life.

If an investigator believes immediate use of the test article is required to preserve the subject’s life and there is insufficient time to obtain an independent physician’s determination that the four conditions above apply, the clinical investigator may alone make the decision to use the test article.   The investigator  must then have his/her decision reviewed and an evaluation made in writing by a physician not participating in the clinical investigation.  This review and evaluation must be made within 5 working days of the use of the test article.  The investigator must also notify the IRB within 5 working days after the use of the test article [21 CFR 50.23(c)].

When non-therapeutic or therapeutic research that does not involve the use of a non-approved drug or device is considered in an emergency setting (not necessarily for the purpose of the emergency itself), proper consent procedures must be followed. Federal regulations offer some flexibility for such research; however, there are still appreciable requirements for which adherence is mandatory. In addition, Florida statutes (in particular the Medical Practice Act) are more restrictive for research in emergency settings than are federal regulations and may override the latter.

A template “Investigational Product Consent Form,” which may be amended to specific situations, is available on the HSRO website.

Footer Block

University of Miami Office of Research UM School of Medicine CITI Program Jackson Health System
 University of Miami logo University of Miami
Human Subjects Research Office

1500 NW 12th Avenue, Ste. 1002, Miami, FL 33136
Tel. 305-243-3195
Copyright, University of Miami, All Rights Reserved
Requests for information. Send technical feedback.
View Privacy statement